Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022

Janux Therapeutics, Inc.

2022-Q3 EPS reported -$1.10 revenue$2,021,000

Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.
R&D expenses $8.4M (vs $0.8M in Q3 2020); G&A $3.6M (vs $0.4M).
PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
TRACIr costimulatory bispecific candidate selection planned in 2022.
Board strengthened with appointments of Ron Barrett (Ph.D.) and Alana McNulty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.